AI Stock Analysis - Regeneron (REGN)
Analysis generated January 2, 2026.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron’s product pipeline includes several groundbreaking therapeutics, and it maintains a strong focus on innovation through cutting-edge research. The company’s major revenue drivers include drugs like EYLEA (for eye diseases), Dupixent (for atopic dermatitis, asthma, and other disorders), and Libtayo (for various cancers). Regeneron’s business model leverages collaboration with other industry players, helping it to broaden its reach and improve its market positioning.
Stock Alerts - Regeneron (REGN)
 |
Regeneron | March 4 Insider Alert: RYAN ARTHUR F is selling shares |
|
Regeneron | February 24 Insider Alert: Zoghbi Huda Y is selling shares |
|
Regeneron | February 12 Insider Alert: Pitofsky Jason is selling shares |
|
Regeneron | February 10 News Alert: Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy |
Download our app to get future alerts delivered in real-time.
Alternative Data for Regeneron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 421 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 313,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 405 | Sign up | Sign up | Sign up |
| Facebook Followers | 22,159 | Sign up | Sign up | Sign up |
| Instagram Followers | 18,211 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,590 | Sign up | Sign up | Sign up |
| X Followers | 33,464 | Sign up | Sign up | Sign up |
| X Mentions | 35 | Sign up | Sign up | Sign up |
| News Mentions | 4 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $203,000 | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 16,618 | Sign up | Sign up | Sign up |
About Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
| Price | $746.61 |
| Target Price | Sign up |
| Volume | 697,070 |
| Market Cap | $81.6B |
| Year Range | $536 - $811.29 |
| Dividend Yield | 0.45% |
| PE Ratio | 18.62 |
| Analyst Rating | 73% buy |
| Industry | Biotechnology |
In the news
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer TreatmentMarch 10 - GlobeNewswire |
|
Inmazeb (Regeneron Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
|
 |
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trialMarch 9 - Techtarget.com |
Regeneron Announces Investor Conference PresentationMarch 5 - GlobeNewswire |
|
 |
Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron”March 4 - Yahoo Entertainment |
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge FundsFebruary 27 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 3.88B | 285M | 3.6B | 845M | 880M | 11.440 |
| Q3 '25 | 3.75B | 522M | 3.23B | 1.46B | 1.92B | 11.830 |
| Q2 '25 | 3.68B | 530M | 3.15B | 1.39B | 1.66B | 12.890 |
| Q1 '25 | 3.03B | 464M | 2.56B | 809M | 1.04B | 8.220 |
| Q4 '24 | 3.79B | 565M | 3.22B | 918M | 1.1B | 12.070 |
Insider Transactions View All
| RYAN ARTHUR F filed to sell 17,743 shares at $787.3. March 3 '26 |
| RYAN ARTHUR F filed to sell 17,786 shares at $780.7. March 3 '26 |
| RYAN ARTHUR F filed to sell 17,789 shares at $779.7. March 3 '26 |
| RYAN ARTHUR F filed to sell 17,745 shares at $786.6. March 3 '26 |
| RYAN ARTHUR F filed to sell 17,763 shares at $784.5. March 3 '26 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Jun 10, 25 | Buy | $1K - $15K |
| Byron Donalds |
May 26, 25 | Sell | $1K - $15K |
| Rob Bresnahan |
Mar 28, 25 | Sell | $1K - $15K |
Read more about Regeneron (REGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Regeneron
The Market Cap of Regeneron is $81.6B.
As of today, Regeneron's PE (Price to Earnings) ratio is 18.62.
Currently, the price of one share of Regeneron stock is $746.61.
The REGN stock price chart above provides a comprehensive visual representation of Regeneron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regeneron shares. Our platform offers an up-to-date REGN stock price chart, along with technical data analysis and alternative data insights.
Yes, Regeneron (REGN) offers dividends to its shareholders, with a dividend yield of 0.45%. This dividend yield represents Regeneron's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Regeneron in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Regeneron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
